Jun 8, 2026 08:00AM
Jun 8, 2026 08:00AM
May 26, 2026 07:00PM
Apr 27, 2026 07:00PM
Mar 16, 2026 07:00AM
Jan 29, 2026 06:01PM
Jan 29, 2026 06:00PM MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
Jan 6, 2026 09:00AM
Dec 18, 2025 06:01AM
Dec 18, 2025 06:00AM
Dec 8, 2025 06:00AM
Dec 8, 2025 06:00AM
Nov 18, 2025 06:01AM
Nov 18, 2025 06:00AM MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
Nov 6, 2025 06:00PM
Nov 4, 2025 07:00AM
Oct 30, 2025 07:00PM
Oct 6, 2025 08:00AM
Sep 22, 2025 08:03AM
Sep 22, 2025 08:00AM
Sep 16, 2025 08:00AM MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
Sep 8, 2025 09:02AM
Sep 8, 2025 09:00AM
Sep 3, 2025 07:00AM
Aug 26, 2025 07:00PM
Jul 31, 2025 07:31PM
Jul 31, 2025 07:30PM
Jul 24, 2025 06:01AM MediciNova nears completion of two clinical trial enrollments
Jul 24, 2025 06:00AM
Apr 14, 2025 07:00PM
Apr 8, 2025 07:00PM
Dec 5, 2024 06:00PM
Nov 19, 2024 09:02AM
Nov 19, 2024 09:00AM
Nov 14, 2024 06:00PM MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
Nov 11, 2024 06:00PM
Oct 23, 2024 07:00PM
Sep 30, 2024 09:00AM
Sep 9, 2024 07:00PM
Sep 3, 2024 07:00PM
Aug 29, 2024 07:00PM
Jun 20, 2024 06:00AM MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
Jun 5, 2024 06:00AM
Jun 5, 2024 06:00AM
Jun 3, 2024 06:00AM
Jun 3, 2024 06:00AM
May 28, 2024 06:00AM
May 20, 2024 06:01AM
May 20, 2024 06:00AM MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
May 14, 2024 06:00AM

322,969 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All